TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00395720

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A (TB vaccine)
Description: Intradermal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA85A (TB vaccine)
Description: Intradermal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Intradermal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Intradermal vaccine
Study: NCT01072500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
Study: NCT03225833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride
Study: NCT02509663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery
Description: Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery using rigide instrumentation
Description: FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinuplasty balloon
Description: Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscope
Description: FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening.
Study: NCT03270527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High SFA diet (Diet 1)
Description: 'Diet 1' will contain \~18% of its total energy as SFA .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low SFA diet (Diet 2)
Description: 'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
Study: NCT02137902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco/Physical Activity Intervention
Description: Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus BP/CHOL Intervention
Description: Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
Study: NCT00597129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4
Description: Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
Study: NCT02522715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02465957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aNK (NK-92)
Description: A natural killer cell line recovered from a patient with large granular lymphoma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aNK (NK-92) + N-803
Description: aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
Study: NCT02522715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT00940394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation group
Description: bi-weekly, 12-session, family psychoeducation group

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
Study: NCT01915355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser for the treatment of nail fungus
Description: The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
Study: NCT03800758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factual Writing
Description: Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
Study: NCT00323518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velafermin
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Study: NCT02878135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast application

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: slow application
Study: NCT00323518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velafermin
Description: administered intravenously as 100mL single dose over 15 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velafermin
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Study: NCT02006394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: fish oil capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol Capsules
Description: delphinidin polyphenol capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil Capsules
Description: Corn Oil Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch capsules
Description: Maltodextrin capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced glycemic index bread products
Description: Made by Zone Labs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Market variety bread products
Description: placebo bread products
Study: NCT00204763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air filled balloon catheter
Description: The new air filled balloon catheter will be tested against the solid state catheter
Study: NCT00323518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Study: NCT00204763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solid state catheter
Description: The standardly used solid state catheter will be tested against the new air filled balloon catheter
Study: NCT04105933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS-CBT
Description: Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
Study: NCT03008083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 months DAPT
Description: Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 months DAPT
Description: Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Study: NCT02567955

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunogenicity two doses of Gardasil-9
Description: Subjects will receive two standard doses of Gardasil-9 (0.5 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunogenicity Cervarix and Gardasil-9
Description: Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
Study: NCT04352114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3461767 - SC
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3461767 - IV
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC.
Study: NCT04217746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
Study: NCT01675687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Up Support
Description: inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Up Support
Description: inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
Study: NCT02029950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT00807807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Folic Acid
Description: Placebo folic acid once a day for 6 weeks
Study: NCT03432546

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT01618552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEE IT training
Description: Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge enhancement
Description: Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
Study: NCT00114465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 1 sachet twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 sachel twice a day
Study: NCT00514033

Intervention type: BIOLOGICAL
Intervention: Poliomyelitis vaccine (inactivated) -PoliorixTM
Description: Deep intramuscular injections for the primary vaccination and booster vaccination.
Study: NCT00987077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Retina Therapy (SRT)
Description: SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Retina Therapy (SRT)
Description: SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
Study: NCT03559465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood punction
Description: 1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood punction
Description: 1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
Study: NCT00993291

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Frequency change to 60 Hz
Description: 60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Frequency change to 130 Hz
Description: 130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
Study: NCT01117428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.
Study: NCT03018028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily
Study: NCT01314833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Cyclophosphamide
Description: Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
Description: 1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Cyclophosphamide Paclitaxel
Description: 1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4
Study: NCT01463319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: air insufflation
Description: air insufflation during insertion phase colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm water irrigation
Description: warm water irrigation during insertion phase colonoscopy
Study: NCT03540966

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CapulinTM
Description: a kind of camouflage agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese version of the vitiligo life quality index, VLQI-C
Description: a questionaire designed for patients with vitiligo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chinese version of the vitiligo life quality index, VLQI-C
Description: a questionaire designed for patients with vitiligo
Study: NCT03018028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Subcutaneous (s.c., under the skin) injection once daily
Study: NCT02391155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single lumen needle in oocyte retrieval
Description: single lumen needle use during oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single lumen needle in oocyte retrieval
Description: single lumen needle use during oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double lumen needle in oocyte retrieval
Description: after aspiration of follicles, 3 times flushing will be performed in double lumen needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double lumen needle in oocyte retrieval
Description: after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
Study: NCT02232542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine - high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00991055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)
Study: NCT00539409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Description: Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Study: NCT00591942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full ceramic crowns or 3-unit fixed partial dentures.
Description: Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
Study: NCT03983915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Study: NCT03030690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass Carbomer Cement
Description: Restoration of proximal lesions in primary molars using glass carbomer cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Composite Resin
Description: Restoration of proximal lesions in primary molars using composite resin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Modified Glass Ionomer Cement
Description: Restoration of proximal lesions in primary molars using resin modified glass ionomer cement